Moнтелукаст Акорд (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Moнтелукаст Акорд, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used for maintenance therapy of asthma and for relief of symptoms of allergic rhinitis in adults and children.

GNH USA supplies Moнтелукаст Акорд as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast works within the leukotriene pathway to manage chronic respiratory conditions. - Asthma: reduces frequency and severity of bronchospasm and improves overall control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate discomfort often reported. - Abdominal pain: intermittent stomach discomfort. - Cough: occasional dry cough. - Nausea: feeling of queasiness. - Dizziness: transient light‑headedness. - Fatigue: unusual tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic injury: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin reactions. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis. - Blood dyscrasias: rare blood cell abnormalities.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: safety data are limited; use only if clearly needed. - Breastfeeding: montelukast is excreted in milk; weigh benefits against potential risks. - Hepatic impairment: monitor liver function and adjust use if necessary. - Neuropsychiatric monitoring: observe patients for mood changes or suicidal ideation. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase montelukast plasma levels. - Phenobarbital, carbamazepine, phenytoin: may significantly reduce montelukast exposure.

Moderate Interactions (Monitor Closely): - Ritonavir: can raise montelukast concentrations. - Warfarin: occasional reports of altered INR; monitor coagulation. - Theophylline: may require dose adjustment of the bronchodilator. - Antidepressants: monitor for additive neuropsychiatric effects.